All In Biotech

Drug Trial Radar · NCT05143996

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Phase 1/2, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

275

Planned (sponsor's estimate)

Start

Nov 18, 2021

Primary completion

Dec 30, 2029

Study completion Dec 30, 2029

Sponsor

Lead sponsor
Cullinan Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Dec 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CLN-049-001 is a Phase 1/2, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • TP53-mutated MDS and AML

Interventions

  • CLN-049Drug

    \[FLT3\] x \[CD3\] bispecific T cell engager

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment emergent events (TEAEs)Time frame: 28 days
  2. Cmax of CLN-049Time frame: Up to 13 weeks
  3. Ctrough of CLN-049Time frame: 28 Days
  4. Tmax of CLN-049Time frame: 28 Days
  5. T1/2 of CLN-049Time frame: Up to 28 days
  6. Efficacy of CLN-049Time frame: Up to 13 weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama O'Neal Cancer Center

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Hospital - Phoenix

    Phoenix, Arizona · Not yet recruiting

  • City of Hope

    Duarte, California · Not yet recruiting

  • UCLA

    Los Angeles, California · Recruiting

  • UCHealth Anschutz Cancer Pavilion

    Aurora, Colorado · Not yet recruiting

  • Mayo Clinic Hospital - Jacksonville

    Jacksonville, Florida · Not yet recruiting

  • University of Miami Health System

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Completed

  • Mayo Clinic Hospital - Rochester

    Rochester, Minnesota · Not yet recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • New York University

    New York, New York · Recruiting

  • New York-Presbyterian / Weill Cornell Medical Center

    New York, New York · Not yet recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Withdrawn

  • MD Anderson

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.